Form 4: RxSight CEO Ronald Kurtz Sells 40,000 Shares Under 10b5-1 Plan

RxSight's CEO, Ronald M. Kurtz, sold 40,000 shares of common stock at an average price of $60.1468 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 3, 2024, Ronald M. Kurtz, the President and CEO of RxSight, Inc., sold 40,000 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on September 15, 2023.
• The shares were sold at a weighted average price of $60.1468, with individual prices ranging from $60.00 to $60.92.
• Following the transaction, Kurtz directly owns 40,000 shares and indirectly owns 764,610 shares through Cricklewood LP.
• Kurtz shares voting and investment control of the general partner of Cricklewood LP with his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.

Industry Context

Sales by insiders are a common occurrence, and the use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates